Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29619439 | 0.98 | NPSR1 (0.34) | NPSR1SMN1; SMN2KCNA3LMNAPDE4A | |
| SCHEMBL231396 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL27585730 | 0.80 | NPSR1 (0.41) | NPSR1LMNAMEN1KMT2ACYP4F2 | |
| Bromide SCHEMBL21798034 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL233616 | 0.80 | — | — | |
| SCHEMBL21469230 | 0.79 | POLB (0.41) | SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL5663490 | 0.79 | MAPK1 (0.36) | — | |
| SCHEMBL12462742 | 0.78 | NPSR1 (0.38) | NPSR1SMN1; SMN2KCNA3LMNAPDE4A | |
| SCHEMBL1433032 | 0.78 | — | — | |
| SCHEMBL331908 | 0.78 | NPSR1 (0.50) | NPSR1SMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092069-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2026-04-02 | — | — | US | disclosed |
| US-12448385-B2 | Substituted indazoles as IRAK4 inhibitors | ASTRAZENECA AB (SE) | 2025-10-21 | — | — | US | disclosed |
| EP-3774761-B1 | METHOD FOR THE PREPARATION OF CYCLOHEXANAMINO ACID ESTERS AND SPIROKETAL SUBSTITUTED CYCLIC KETOENOLS | BAYER AG (DE) | 2024-09-11 | — | — | EP | disclosed |
| US-20240294539-A1 | PROCESS FOR PREPARING SUBSTITUTED CYCLOHEXANE AMINO ACID ESTERS AND SPIROKETAL-SUBSTITUTED CYCLIC KETO-ENOLS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-09-05 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12006327-B2 | Process for preparing substituted cyclohexane amino acid esters and spiroketal-substituted cyclic keto-enols | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-11 | — | — | US | disclosed |
| US-20240182479-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-06 | — | — | US | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2014160649-A1 | HYDROXAMIC ACID DERIVATIVES AS LPXC INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| EP-1893246-A4 | STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGS FOR TUMOR IMAGING | UNIV EMORY (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1893246-A2 | STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGS FOR TUMOR IMAGING | Emory University (US) | 2008-03-05 | — | — | EP | disclosed |
| CN-101098852-A | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof | SMITHKLINE BEECHAM CORP (US) | 2008-01-02 | — | — | CN | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007001958-A2 | STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGS FOR TUMOR IMAGING | EMORY UNIVERSITY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007001958-A2 | STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGS FOR TUMOR IMAGING | EMORY UNIVERSITY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060292073-A1 | Stereoselective Synthesis of Amino Acid Analogs for Tumor Imaging | EMORY UNIVERSITY (US) | 2006-12-28 | — | — | US | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060292073-A1 | Stereoselective Synthesis of Amino Acid Analogs for Tumor Imaging | PAICS, BCAT1, SLC1A5 | NPSR1 1313/4885SMN1; SMN2 1824/4885KCNA3 3555/4885 |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | NPSR1 4240/4885SMN1; SMN2 2240/4885KCNA3 3997/4885 |
| US-20260092069-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | IRAK3, IRAK4, IRAK2 | NPSR1 3295/4885SMN1; SMN2 1935/4885KCNA3 1905/4885 |
| US-20240294539-A1 | PROCESS FOR PREPARING SUBSTITUTED CYCLOHEXANE AMINO ACID ESTERS AND SPIROKETAL-SUBSTITUTED CYCLIC KETO-ENOLS | BCAT1, BCAT2, BCKDK | NPSR1 1012/4885SMN1; SMN2 4273/4885KCNA3 767/4885 |
| US-12448385-B2 | Substituted indazoles as IRAK4 inhibitors | IRAK4, IRAK1, IRAK2 | NPSR1 4370/4885SMN1; SMN2 3732/4885KCNA3 1462/4885 |
| US-12006327-B2 | Process for preparing substituted cyclohexane amino acid esters and spiroketal-substituted cyclic keto-enols | BCAT1, BCAT2, BCKDK | NPSR1 1012/4885SMN1; SMN2 4273/4885KCNA3 767/4885 |
| US-20240182479-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK2 | NPSR1 4282/4885SMN1; SMN2 2315/4885KCNA3 2731/4885 |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | NPSR1 4599/4885SMN1; SMN2 40/4885KCNA3 3643/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | NPSR1 98/4885SMN1; SMN2 4686/4885KCNA3 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.